Infliximab in the treatment of rheumatoid arthritis
Infliximab was the first monoclonal antibody to human necrosis factor alpha (TNFα) developed for treating rheumatoid arthritis (RA). This chimeric antibody binds with high affinity to both soluble and trans-membrane TNF and is able to reduce synovial inflammation, bone resorption and cartilage degra...
| Main Author: | |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2009
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726073/ |